AptaTargets
Last verified 2026-05-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $7.0Mattributed |
|---|---|
| Latest round | grant, $2.7M, 2024-04-01attributed |
| Founded | 2014 |
| Headquarters | Madrid, Spain |
| Industry | biotech |
| Stage | unknown |
| Website | aptatargets.com |
aptaTargets is a clinical-stage biopharmaceutical developing aptamer-based therapeutics targeting acute inflammatory conditions like ischemic stroke. It serves patients suffering from stroke, intracerebral hemorrhage, myocardial infarction, and multiple sclerosis. Its lead candidate ApTOLL is the only drug in development that treats stroke by blocking TLR4 activation, a neuroprotective mechanism now licensed to Merck.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-04-01 | grant | $2.7M | undisclosed |
Detected tech stack
Nginx 1.29.2, Yoast SEO 13.2, Google Analytics, Google Tag Manager, Slider Revolution, jQuery Migrate 1.4.1, DoubleClick Floodlight, React, PHP, MySQL, wordpress ., jquery 1.1
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Total raised $7.0M | attributed | eu-grant named as publisher. No document URL on file. |
| Company existence | self-reported | aptatargets.com, read 2026-05-02 |
| Description | self-reported | aptatargets.com, read 2026-05-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.